I
IDEAYA Biosciences, Inc. (IDYA)
NMS – Real vaqt narxi. Valyuta: USD
30.46
-1.63 (-5.08%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
30.46
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:34 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NMS – Real vaqt narxi. Valyuta: USD
30.46
-1.63 (-5.08%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
30.46
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:34 PM EDT
IDEAYA Biosciences, Inc., aniq tibbiyot onkologiya kompaniyasi, Qo'shma Shtatlarda molekulyar diagnostika yordamida tanlangan bemorlar populyatsiyalari uchun maqsadli terapevtik vositalarni kashf etadi va ishlab chiqadi. Kompaniya uveal melano-ma, GNAQ/11 mutatsiyalari keltirib chiqaradigan ko'z saratonini davolash uchun og'iz orqali qabul qilinadigan, kuchli va selektiv protein kinaz C (PKC) inhibitore hisoblangan Darovasertibni taklif etadi va ko'plab klinik tadqiqotlarda monoterapevtik va krizo-tinib bilan birgalikda metastatik, neoad'yuvant va ad'yuvant holatlar uchun baholanmoqda. Kompaniya, shuningdek, SCLC va neyroendokrin karsinomani davolash uchun 1-bosqich klinik tadqiqotida bo'lgan DLL3 antitel-dorivor kon'yugati inhibitore bo'lgan IDE849; IDE034, B7H3/PTK7 topo-I-payload bispesifik BsADC; 1-bosqich dozani optimallashtirish tadqiqotida bo'lgan pol-i(ADP-riboza)-glikogidrolaza inhibitore bo'lgan IDE161; BRCA yoki HRD bilan bog'liq boshqa mutatsiyalarga ega o'smalarni davolash uchun 1-bosqich klinik tadqiqotida bo'lgan Poly Theta Helicase inhibitore bo'lgan IDE705 (GSK101); MTAP-deleted o'smalar uchun MAT2A inhibitore bo'lgan IDE397; PRMT5 inhibitore bo'lgan IDE892; KAT6/7 ni selektiv ravishda ingibitsiya qiluvchi va ko'krak, o'pka, prostata va kolorektal saratoni bo'lgan bemorlar uchun 1-bosqich dozani oshirish tadqiqotida bo'lgan IDE574; Werner proteini (WRN) helikaza domenining og'iz orqali qabul qilinadigan kichik molekula inhibitore bo'lgan va 1-bosqich klinik tadqiqotida bo'lgan IDE275 ni taklif etadi. Bundan tashqari, kompaniya farmakologik ingibitsiyaga qaratilgan preklinik tadqiqot dasturlarini; sintetik letallik maqsadi va biomarkerlarni kashf qilish uchun DECIPHER dual CRISPR kutubxonasini; va uning dorilarni kashf qilish platformasini yaxshilash uchun INQUIRE kimyoviy kutubxonasi va HARMONY mashinani o'rganish mexanizmlarini taklif etadi. Kompaniya GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, Manchester Universiteti, Jiangsu Hengrui Pharmaceuticals Co., Ltd. va Les Laboratoires Servie bilan strategik ittifoqlarga ega. IDEAYA Biosciences, Inc. 2015 yilda tashkil etilgan va AQShning Kaliforniya shtati, Janubiy San-Fransiskoda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Darrin M. Beaupre M.D., Ph.D. | Chief Medical Officer |
| Dr. Joshua Bleharski Ph.D. | Chief Financial Officer |
| Dr. Michael A. White Ph.D. | Chief Scientific Officer |
| Dr. Paul A. Barsanti Ph.D. | Chief Technology Officer |
| Mr. Andres Ruiz Briseno CPA | Chief Accounting Officer |
| Mr. Douglas B. Snyder | Chief Legal Officer |
| Mr. Mick O'Quigley | Senior Vice President of Medical Writing & Project Management |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-12 | 8-K | d93674d8k.htm |
| 2025-12-12 | 8-K | d800445d8k.htm |
| 2025-12-05 | 8-K | d87387d8k.htm |
| 2025-11-04 | 10-Q | idya-20250930.htm |
| 2025-10-20 | 8-K | d42028d8k.htm |
| 2025-09-08 | 8-K | d38716d8k.htm |
| 2025-09-02 | 8-K | d800731d8k.htm |
| 2025-08-05 | 8-K | idya-20250805.htm |
| 2025-06-27 | 8-K | d28084d8k.htm |
| 2025-06-24 | 8-K | d909229d8k.htm |
| Mr. Stuart C. Dorman |
| Chief Commercial Officer |
| Mr. Yujiro S. Hata | Founder, President, CEO & Director |
| Ms. Francine Zelaya | Senior VP & Head of Human Resources |